Visionary Ventures
Venture capitalNewport Beach Β· Series AβLate Stage Β· 9 people tracked
Investment thesis
The firm believes superior information and access to domain expertise drive better investment outcomes. By partnering with key opinion leaders, industry specialists, and strategic acquirers, they identify and fund visionary entrepreneurs building market-leading businesses in underserved sectors. The investment thesis emphasizes both financial returns and positive societal impact, leveraging expert networks for rigorous deal sourcing, vetting, and guidance throughout the investment process.
Source: firm website, verified Jul 21, 2026.
Team Β· 9 people
from the firm's websiteFounding managing partner with over 30 years of private equity experience. Previously founded the Investment Banking and Capital Markets groups at Jefferies & Co., served as Head of Investment Banking and Board Member, and was a partner at Drexel Burnham Lambert.
Eight-year veteran who drives due diligence, valuations, transaction execution, and portfolio management. Has supported multiple ophthalmology company acquisitions and an IPO, generating nearly $3 billion in cumulative value. Holds an MBA in Finance and Data Science from USC Marshall and a Bachelor of Engineering from Vanderbilt.
30+ year pharmaceutical R&D veteran currently serving as CEO of Pelage Pharmaceuticals. Previously led research groups at Allergan with oversight of preclinical to early clinical development, generating 13 drug candidates and authoring 42 peer-reviewed articles. Holds degrees from Harvard and University of Pennsylvania.
Over 30 years of commercial leadership across ophthalmology, with 15 years in eye care spanning roles at Novartis, Bausch & Lomb, and Shire. Key contributor to the FDA approval and launch of Xiidra for dry eye disease and participated in Shire's acquisition by Takeda.
Investment committee member and CEO of OCTANe with prior experience as an operating partner at Blackstone.
Investment committee member, international lecturer on retinal diseases, and founder of the California Retina Research Foundation.
Investment committee member and internationally recognized leader in corneal, cataract, refractive and laser surgery.
Investment committee member and CEO & Founder of Visionary Eye Institute who has delivered over 300 invited lectures.
Investment committee member who serves on numerous editorial boards and is a partner and founder of Tyson Eye.
What they invest in
from 1 of 15 portfolio companiesMedical Devices Γ1
HQs:United StatesΓ1
Investments Β· 15 tracked
founders shown can be your intro pathIantrek develops medical devices and technologies for micro-interventional ophthalmic surgery, specifically targeting glaucoma treatment through uveoscleral pathway outflow enhancement for surgeons and ophthalmologists.
Medical DevicesElkins Park, US
Frequently asked questions
- What stage does Visionary Ventures invest at?
- Visionary Ventures invests at the Series A, Growth, Late Stage stages.
- What is Visionary Ventures's typical check size?
- Visionary Ventures typically writes checks of $5M β $15M.
- What sectors does Visionary Ventures focus on?
- Visionary Ventures focuses on Digital Health, Medical Devices, Sector Agnostic.
- Where is Visionary Ventures located?
- Visionary Ventures is headquartered in Newport Beach, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Kleiner Perkins is a venture capital firm that invests across early-stage and growth companies, with a portfolio spanning multiple sectors and geographies. The firm has been active since 1972 and is known for backing transformative technology companies.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.